06/10/2026 | Press release | Distributed by Public on 06/10/2026 14:17
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
20-5455398
(I.R.S. Employer
Identification No.)
|
|||||||||||||||||||
|
6000 Shoreline Court, Suite 300
South San Francisco, California
(Address of Principal Executive Offices)
|
94080
(Zip Code)
|
|||||||||||||||||||
| Veracyte, Inc. 2023 Equity Incentive Plan | ||||||||||||||||||||
| (Full title of the plan) | ||||||||||||||||||||
|
Marc Stapley
Chief Executive Officer
6000 Shoreline Court, Suite 300
South San Francisco, California
(Name and address of agent for service)
(650) 243-6300
(Telephone number, including area code, of agent for service)
Copies to:
|
||||||||||||||||||||
|
Jim Krenn, Esq.
Morrison & Foerster LLP
12531 High Bluff Drive
San Diego, CA 92130
(858) 720-5100
|
Emily Beers, Esq. Morrison & Foerster LLP 2100 L Street NW, Suite 900 Washington, D.C. 20037 (202) 887-1500 |
Annie McGuire, Esq.
Executive Vice President and
General Counsel
Veracyte, Inc.
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
(650) 243-6300
|
||||||||||||||||||
| Large accelerated filer | ☒ | Accelerated filer | ☐ | |||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||||||||||
| Emerging growth company | ☐ | |||||||||||||
| Item 8. | Exhibits. | ||||
|
The following exhibits are filed herewith:
|
|||||
| Incorporated by Reference | ||||||||||||||||||||
| Exhibit No. | Description | Form | File No. | Exhibit | Filing Date | Filed Herewith | ||||||||||||||
| 4.1 | 8-K | 001-36156 | 3.2 | 6/9/2023 | ||||||||||||||||
| 4.2 | 10-Q | 001-36156 | 3.2 | 5/6/2026 | ||||||||||||||||
| 4.3 | S-1/A | 333-191282 | 4.1 | 10/15/2013 | ||||||||||||||||
| 5.1 |
Opinion of Morrison & Foerster LLP
|
X | ||||||||||||||||||
| 23.1 |
Consent of Independent Registered Public Accounting Firm
|
X | ||||||||||||||||||
| 23.2 |
Consent of Morrison & Foerster LLP (included in Exhibit 5.1)
|
X | ||||||||||||||||||
| 24.1 |
Power of Attorney (contained on signature page hereto).
|
X | ||||||||||||||||||
| 99.1 | DEF 14-A | 001-36156 | Appendix A | 4/22/2026 | ||||||||||||||||
| 99.2 | S-8 POS | 333-270147 | 99.6 | 6/8/2023 | ||||||||||||||||
| 107.1 |
Filing Fee Table
|
X | ||||||||||||||||||
| VERACYTE, INC. | |||||||||||
| By: | /s/ MARC STAPLEY | ||||||||||
|
Marc Stapley
Chief Executive Officer and Director
|
|||||||||||
| Signature | Title | Date | ||||||||||||
| /s/ MARC STAPLEY |
Chief Executive Officer and Director (Principal Executive Officer) |
June 10, 2026 | ||||||||||||
| Marc Stapley | ||||||||||||||
| /s/ REBECCA CHAMBERS |
Chief Financial Officer (Principal Financial Officer) |
June 10, 2026 | ||||||||||||
| Rebecca Chambers | ||||||||||||||
| /s/ JONATHAN WYGANT | Chief Accounting Officer (Principal Accounting Officer) | June 10, 2026 | ||||||||||||
| Jonathan Wygant | ||||||||||||||
| /s/ ROBERT S. EPSTEIN, M.D., M.S. | Chairperson and Director | June 10, 2026 | ||||||||||||
| Robert S. Epstein, M.D., M.S. | ||||||||||||||
| /s/ ELIAV BARR, M.D. | Director | June 10, 2026 | ||||||||||||
| Eliav Barr, M.D. | ||||||||||||||
| /s/ MUNA BHANJI | Director | June 10, 2026 | ||||||||||||
| Muna Bhanji | ||||||||||||||
| /s/ KARIN EASTHAM | Director | June 10, 2026 | ||||||||||||
| Karin Eastham | ||||||||||||||
| /s/ JENS HOLSTEIN | Director | June 10, 2026 | ||||||||||||
| Jens Holstein | ||||||||||||||
| /s/ EVAN JONES | Director | June 10, 2026 | ||||||||||||
| Evan Jones | ||||||||||||||
| /s/ TOM MILLER | Director | June 10, 2026 | ||||||||||||
| Tom Miller | ||||||||||||||
| /s/ BRENT SHAFER | Director | June 10, 2026 | ||||||||||||
| Brent Shafer | ||||||||||||||